39 results about "Protective immunity" patented technology

A varicella-zoster vaccine composition and use thereof, belonging to the technical field of biological vaccines. The composition comprises a VZV gE antigen and a CpG ODN adjuvant and further comprises an aluminum adjuvant. The nucleotide sequence of the CpG ODN adjuvant is set forth in SEQ ID NO: 1. The CpG ODN adjuvant with a specific nucleotide sequence has better immunostimulatory activity. The provided varicella-zoster vaccine composition can generate a higher humoral immune response earlier and induce protective immunity in advance for at least one month. One immunization can reach or be close to the antibody level of two immunizations of the Shingrix vaccine. Moreover, the longer-time stable high-humoral immunity level can be kept, and cellular immunity can also be generated.

The invention discloses a varicella zoster vaccine composition and application thereof, and belongs to the technical field of biological vaccines, the composition comprises a VZV gE antigen, a CpG ODN adjuvant and an aluminum adjuvant, and the nucleotide sequence of the CpG ODN adjuvant is shown as SEQ ID NO: 1. According to the invention, the CpG ODN adjuvant with a specific nucleotide sequence is selected, so that the immunostimulatory activity is better; the varicella zoster vaccine composition provided by the invention can generate high humoral immune response earlier, and induces protective immunity for at least one month in advance; the antibody level of twice immunization of a Shigrix vaccine can be reached or close to once immunization, the stable high humoral immune level for a long time can be kept, and meanwhile cellular immunity can be generated.

Waning immunity induced by first-generation Spike-alone-based COVID-19 has failed to prevent immune escape by many variants of concern (VOCs) that emerged from 2020 to 2024, resulting in a prolonged COVID-19 pandemic. Thus, a next-generation Coronavirus (CoV) vaccine incorporating highly conserved non-Spike SARS-CoV-2 antigens is described herein. Conserved non-Spike T cell antigens in combination with a Spike antigen encapsulated in lipid nanoparticles: (i) Induced high frequencies of lung-resident antigen-specific CXCR5+CD4+ T follicular helper cells, GzmB+CD4+ and GzmB+CD8+ cytotoxic T cells, and CD69+IFN-γ+TNFα+CD4+ and CD69+IFN-γ+TNFα+CD8+ effector T cells; and (ii) Reduced viral load and COVID-19-like symptoms caused by various VOCs. The combined antigen / LNP-based pan-CoV vaccine could be rapidly adapted for clinical use to confer broader cross-protective immunity against emerging highly mutated and pathogenic VOCs.

The invention belongs to the technical field of biology, and relates to an immunocompetence composition and a pertussis vaccine containing the immunocompetence composition. The immunocompetence composition comprises pertussis Bordetella outer membrane vesicles and attenuated pertussis toxins in a weight ratio of (5-50): (5-25). Effective protective immunity can be triggered in the process of preventing pertussis infection, pertussis bacteria in the lung are effectively eradicated, and bacterial colonization in the trachea and the nasal cavity is remarkably reduced.

The invention provides a method of preparing a vaccine composition. The method includes infecting gene-edited porcine endogenous retrovirus (PERV) negative swine cells with a microorganism which expresses at least one protein antigen capable of inducing protective immunity in an animal against an infectious agent; culturing the infected cells in culture medium to propagate the microorganism; and harvesting the propagated microorganism from the culture medium to obtain a fraction comprising a PERV free antigen for use in immunizing an animal against the infectious agent.

A vaccine comprising effective amounts of i) E. coli colonization factor antigens comprising CFA / I, CS3, CS5 and CS6 antigens; ii) a heat labile enterotoxin B subunit antigen being an LCTBA protein; and iii) an adjuvant being double mutant (R192G / L211A) of E. coli heat-labile toxin (dmLT), for use in inducing protective immunity against diarrheal disease caused by Salmonella spp. and / or Shigella spp.

The invention provides a method of preparing a vaccine composition. The method includes infecting gene-edited porcine endogenous retrovirus (PERV) negative swine cells with a microorganism which expresses at least one protein antigen capable of inducing protective immunity in an animal against an infectious agent; culturing the infected cells in culture medium to propagate the microorganism; and harvesting the propagated microorganism from the culture medium to obtain a fraction comprising a PERV free antigen for use in immunizing an animal against the infectious agent.

The present invention is directed to providing a canine with protective immunity against Leptospira serovar Grippoty-phosa with a vaccine that comprises a non-Grippotyphosa Leptospira serovar.

The present invention relates to providing protective immunity against Leptospira serovar Icterohaemorrhagiae to dogs using a vaccine comprising a non-Icterohaemorrhagiae Leptospira serotype.

Engineered, replication-deficient influenza viruses that are infectious and stimulate broadly-cross protective immunity against multiple different influenza strains have been developed. Compositions and methods for providing protective immune responses against influenza are provided. The methods deliver compositions of intact, replication-deficient influenza viruses by intradermal administration in an amount effective to elicit or stimulate a cross-protective immune response to influenza viruses in the recipient following a single administration. Because the engineered influenza viruses are non-replicating, they are safe and effective in immunocompromised subjects. Methods for delivering co-stimulatory molecules, growth factors, adjuvants and / or cytokines together with the non-replicating influenza viruses are also provided.

The present disclosure provides a vaccine comprising a modified live PRRS-1 virus attenuated in a cell expressing porcine CD163 for inducing protective immunity in a piglet of 60 hours old or more wherein the vaccine is intranasally administered to the piglet.

A composition comprising isolated Streptococcus pyogenes extracellular vesicles (EVs) suspended in a vehicle, for use in eliciting an adaptive immune response against group A streptococcus (GAS) in a subject. The EVs may comprise antigens MtsA, Spy_1228, PrsA1, PrsA2, SPy_0319 and / or GlnP. A composition comprising isolated S. pyogenes protein(s) MtsA, SPy_1228, PrsA1, PrsA2, GlnP, SPy_0319 and / or MalX. The compositions may be used for inducing protective immunity in a subject against a GAS infection, such as streptococcal pharyngitis, scarlet fever, impetigo, streptococcal meningitis, streptococcal sinusitis, necrotizing fasciitis, cellulitis, streptococcal toxic shock syndrome, rheumatic fever and post-streptococcal glomerulonephritis.

Disclosed herein is a universal species-independent method for characterizing antibodies present in a sample that may provide protective immunity against a given pathogen or antigen of interest.

The present invention provides compositions, vaccines, and methods for inducing protective immunity to immunogens in humans. Protective immune responses are obtained by using saRNA, particularly VRP vectors as a prime and MVA vectors for boosting. Specifically, the present invention relates to genetically engineered (recombinant) VRP and MVA vectors that contain at least one heterologous nucleotide sequence encoding an antigenic determinant of an infectious virus (e.g., EBV).

A composition comprising isolated Streptococcus pyogenes extracellular vesicles (EVs) suspended in a vehicle, for use in eliciting an adaptive immune response against group A streptococcus (GAS) in a subject. The EVs may comprise antigens MtsA, Spy_1228, PrsA1, PrsA2, SPy_0319 and / or GlnP. A composition comprising isolated S. pyogenes protein(s) MtsA, SPy_1228, PrsA1, PrsA2, GlnP, SPy_0319 and / or MalX. The compositions may be used for inducing protective immunity in a subject against a GAS infection, such as streptococcal pharyngitis, scarlet fever, impetigo, streptococcal meningitis, streptococcal sinusitis, necrotizing fasciitis, cellulitis, streptococcal toxic shock syndrome, rheumatic fever and post-streptococcal glomerulonephritis.

The invention provides a ferritin nanoparticle vaccine for preventing giardiasis and a preparation method thereof, and ferritin nanoparticles are used as a vaccine carrier to construct a subunit vaccine for preventing giardiasis. According to the vaccine, the stability and immunogenicity of the antigen are remarkably improved; and by utilizing the characteristics of the nanotechnology, the targeted delivery of the vaccine can be realized, so that the vaccine can act on immune cells more accurately, and the immune response level of the system is effectively improved. The vaccine has the characteristics of low cost, high safety and capability of inducing good protective immunity, and effectively controls giardia infection and propagation thereof.

The invention provides a method of preparing a vaccine composition. The method includes infecting gene-edited porcine endogenous retrovirus (PERV) negative swine cells with a microorganism which expresses at least one protein antigen capable of inducing protective immunity in an animal against an infectious agent; culturing the infected cells in culture medium to propagate the microorganism; and harvesting the propagated microorganism from the culture medium to obtain a fraction comprising a PERV free antigen for use in immunizing an animal against the infectious agent.

The present invention relates to a recombinant protein vaccine for preventing and treating SARS-CoV-2 variant JN.1, BA.2.86, and XBB lineages, a combination drug, and a use. To address significant immune escape and immune imprinting phenomena observed with Omicron JN.1, BA.2.86 and XBB lineage subvariants following prior vaccination or virus infection, an XBB.1.5 recombinant protein vaccine is provided. This vaccine elicits potent humoral and cellular immune responses against currently circulating JN.1, BA.2.86, and XBB lineage variants. Compared with homologous vaccination, heterologous vaccination with this vaccine following administration of an inactivated or mRNA-based vaccine achieves superior immune responses. Moreover, the vaccine induces effective protective immunity against live Omicron EG.5.1 virus attack in vivo. Therefore, the monovalent XBB.1.5 vaccine has clinical use value.

The invention provides a novel adjuvant subunit rabies virus vaccine as well as a preparation method and application thereof, the vaccine takes a rabies virus (RABV) glycoprotein extracellular domain prepared by a gene recombination technology as an antigen, and takes a combination of CpG oligodeoxynucleotide and QS21 as an adjuvant. A contrast experiment is carried out on the vaccine, an LNP-mRNA-G-H270P vaccine, a commercial inactivated vaccine and an aluminum adjuvant subunit vaccine, and the result shows that the vaccine can induce a remarkably higher RABV-G specific IgG antibody and virus neutralizing antibody titer, and the humoral immune response is superior to that of other vaccines; meanwhile, moderate and effective Th1 type cell immune response can be induced, so that protective immunity can be supported; 100% protection is achieved in a lethal RABV attack experiment, and the protection effect is equivalent to that of an mRNA vaccine and is remarkably superior to that of an aluminum adjuvant vaccine and a commercial inactivated vaccine. The vaccine provided by the invention has a controllable immune activation mechanism and relatively high safety, avoids the storage risk and excessive inflammatory response of a nucleic acid technology, and is a more reliable and universal choice in the current vaccine technology.

Helicobacter pylori is a leading cause of gastric mucosal inflammation, peptic ulcers, and gastric adenocarcinoma. Emerging antimicrobial-resistant H. pylori has hampered the successful eradication of frequent chronic infections. Additionally, due to the absence of effective vaccines against H. pylori, a safe vaccine is highly demanded. Disclosed herein are innovative Protective Immunity Enhanced Salmonella Vaccine (PIESV) vector strains to deliver and express multiple H. pylori antigen genes. Immunization of mice with a vaccine delivering the HpaA, NapA (also termed Hp-NAP), UreA and UreB antigens, provided sterile protection against H. pylori SS1 infection in 7 out of 10 tested mice. Compared to the control groups that had received PBS or a PIESV with an empty vector, immunized mice exhibited specific and significant cellular recall responses and antigen-specific IgG2c, IgG1, total IgG and gastric IgA antibody titers. Importantly, the mice immunized with the vaccine candidate showed a significant reduction in a load of an unidentified Gram-positive rod-shaped bacteria in their stomach compared to the control groups. In conclusion, a Salmonella Typhimurium-based live vaccine delivering four antigens shows promise as a safe and effective vaccine against H. pylori infection.

The invention generally relates to the development of immunogenic compositions comprising a DNA copy of at least one live attenuated plus-sense single-stranded RNA virus genome, such as the genome of a live-attenuated Zika vims (ZIKV), Japanese encephalitis virus (JEV) or yellow fever vims (YFV). The immunogenic compositions can be used for treating or conferring protective immunity against diseases related to plus-sense single-stranded RNA viruses, e.g. for affording prolonged immunoprotection against such viruses and protective immunity is conferred at low diseases, e.g., as low as 300 or 500 ng after administration of a single pLAV dosage.

The present invention provides compounds and compositions containing reduced nicotinamide riboside for use in methods of promoting protective immunity and / or for preventing and / or treating bacterial or viral infection and / or for limiting immune-mediated pathology following infection in an individual, including delivering an effective unit dose of reduced nicotinamide to an individual in need thereof.

The invention belongs to the technical field of veterinary vaccines, and particularly relates to fusion protein and nanoparticles of porcine reproductive and respiratory syndrome virus recombinant epitopes and application of the fusion protein and the nanoparticles. A GP3 protein antigen epitope, a GP4 protein antigen epitope, a GP5 protein antigen epitope and an M protein antigen epitope are recombined, the obtained recombinant protein is closely related to protective immunity of the PRRSV, a strong humoral immune response aiming at the PRRSV can be generated after piglets are immunized, and a good protection effect is generated on infection of the PRRSV. The fusion protein is connected with the beta-cyclopeptide, and the beta-cyclopeptide serving as a nano skeleton can spontaneously form 24-surface nanoparticles, so that the antigen can be effectively presented, and the immune effect of the vaccine is promoted. Furthermore, the N terminal of the beta cyclopeptide is connected with an OX40L protein, and the OX40L protein belongs to a tumor necrosis factor ligand superfamily, so that the cellular immune effect can be further improved.

Provided herein are recombinant modified vaccinia Ankara (rMVA) viral vectors comprising heterologous nucleic acid inserts encoding one or more SARS-CoV2 proteins, peptides, or fragments thereof, operably linked to a promoter compatible with poxvirus expression systems that, upon expression, are capable of inducing protective immunity. The compositions can be used in a priming vaccination strategy or in a prime / boost vaccination strategy to provide immunity to SARS-CoV2 and variants thereof.

The invention discloses a monkey pox virus self-assembled nanoparticle and a preparation method and application thereof, and relates to the technical field of monkey pox virus vaccine research and development, the monkey pox virus nanoparticle (NP) is a DAM-NP nanoparticle vaccine formed by covalent coupling of a DAM antigen and SD-Ferritin, the DAM antigen comprises a fusion sequence of monkey pox virus M1 protein and A35 protein, the N end is connected with a GvTagOpti tag, the D-Ferritin is connected with a GvTagOpti tag, and the D-Ferritin is connected with a GvTagOpti tag. The middle parts are connected through a glycine-serine-glycine spacer region; the SD-Ferritin is formed by fusing an SdCatcher fragment and the N end of the helicobacter pylori ferritin, and the SdCatcher fragment and the N end of the helicobacter pylori ferritin are connected through a GSG spacer region; the coupling ratio of the DAM antigen to the SD-Ferritin is 3: 1, and covalent binding is formed after incubation in an assembly buffer solution at 4 DEG C for 24 hours. The monkey pox DAM-NP vaccine is constructed by fusing M1 and A35 antigens of the monkey pox virus in a bivalent form and displaying the M1 and A35 antigens on the surfaces of self-assembled 24-polymer ferritin nanoparticles by using a GvTagOpti / SdCatcher covalent coupling system, antigen-specific body fluid and cellular immune response can be stimulated, and protective immunity can be induced by a single dose of the monkey pox DAM-NP vaccine.

Waning immunity induced by first-generation Spike-alone-based COVID-19 has failed to prevent immune escape by many variants of concern (VOCs) that emerged from 2020 to 2024, resulting in a prolonged COVID-19 pandemic. Thus, a next-generation Coronavirus (CoV) vaccine incorporating highly conserved non-Spike SARS-COV-2 antigens is described herein. Conserved non-Spike T cell antigens in combination with a Spike antigen encapsulated in lipid nanoparticles: (i) Induced high frequencies of lung-resident antigen-specific CXCR5+CD4+ T follicular helper cells, GzmB+CD4+ and GzmB+CD8+ cytotoxic T cells, and CD69+IFN-γ+TNFα+CD4+ and CD69+IFN-γ+TNFα+CD8+ effector T cells; and (ii) Reduced viral load and COVID-19-like symptoms caused by various VOCs. The combined antigen / LNP-based pan-CoV vaccine could be rapidly adapted for clinical use to confer broader cross-protective immunity against emerging highly mutated and pathogenic VOCs.

Provided are compositions, feeds, rations, drinking water and methods of use thereof for inducing protective immunity against or preventing Clostridium perfringens infection and / or necrotic enteritis in poultry, optionally as single dose vaccines. The composition comprises live virulent Clostridium perfringens (CP) and a mucosal adjuvant, such as cholera toxin (CT), which is for administered at or after hatch by for example oral delivery. The composition can be used with an immunomodulatory composition administered in ovo before hatching or a boost composition. The composition can be administered as a single dose.

The present disclosure is directed to novel porcine sapoviruses (SaV) isolates, including SaV serially propagated in cell culture, all of which are useful in the preparation of immunogenic compositions and vaccines for treating and preventing disease in swine. The disclosure further provides characterization of pathogenicity and cross-protective immunity of contemporary porcine SaV isolates in weaned pigs, demonstrating that prior exposure to homologous strains provides greater protection against viral shedding than heterologous strains.

The present invention provides compositions, vaccines and methods for inducing protective immunity against an immunogen in humans. The protective immune response is obtained by using a saRNA, in particular a VRP vector as prime and a MVA for boost. Specifically, the present invention relates to genetically engineered (recombinant) VRP and MVA vectors comprising at least one heterologous nucleotide sequence encoding an antigenic determinant of an infectious virus such as EBV.

Provided herein are live attenuated viruses for protection against respiratory syncytial virus (RSV) and / or coronavirus Sars-CoV-2. The live attenuated chimeric virus strains utilize a master backbone based on a live attenuated influenza virus (LAIV), which includes a deletion of the viral virulence element, the NS1 (non-structural protein 1) (DeLNS1). These chimeric strains are engineered to express one or more antigens of RSV alone or in combination with Sars-CoV-2. The chimeric virus strain can protect a subject in need thereof against a challenge from any of RSV, Sars-CoV-2, influenza, or a combination thereof. This viral vector system offers an important strategy for developing highly attenuated and immunogenic live attenuated vaccines with the capacity to induce protective immunity against the three respiratory infections.